<DOC>
	<DOCNO>NCT02275481</DOCNO>
	<brief_summary>This randomize , open-label , parallel group , multicenter , outpatient study COPD subject discharge hospital due COPD exacerbation . Subjects meet eligibility criterion randomize 1 2 treatment : arformoterol tartrate inhalation solution ( BROVANA ) 15 mcg twice daily ( BID ) tiotropium bromide ( SPIRIVA ) 18 mcg daily ( QD ) , give 90 day .</brief_summary>
	<brief_title>A Study Arformoterol Tartrate Inhalation Solution Tiotropium Bromide Re-hospitalization Chronic Obstructive Pulmonary Disease ( COPD ) Subjects</brief_title>
	<detailed_description>This randomize , open-label , parallel group , multicenter , outpatient study COPD subject discharge hospital follow COPD exacerbation . Subjects meet eligibility criterion randomize 1 2 treatment . Arformoterol tartrate inhalation solution 15 mcg ( BROVANA ) administer BID ( morning evening , approximately 12 hour dos ) use standard jet nebulizer face mask mouthpiece connect air compressor . Tiotropium 18 mcg ( SPIRIVA ) administer QD ( morning ) via HandiHaler® . Study medication dispense subject Visit 1 . The objective study determine comparative effectiveness arformoterol tiotropium re-hospitalization ass safety Chronic Obstructive Pulmonary Disease ( COPD ) subject recover hospitalization acute exacerbation .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Male female subject ≥ 55 yearsold eligible study participation physicianassessed diagnosis COPD , discharge hospital due COPD exacerbation , least 1 follow : 1 . Subject 1 exacerbation ( exclude current exacerbation ) within previous year ( exacerbation define : event natural course disease characterize change patient 's baseline dyspnea , cough /or sputum beyond day day variability sufficient warrant change management COPD ( eg , treat antibiotic and/or systemic corticosteroid require emergency room visit overnight stay hospital ) , OR 2 . Subject oxygen therapy use within 3 month prior study entry . 2 . Subject current exsmoker least 10 pack year smoke history ( eg , least 1 pack/day 10 year , equivalent ) . 3 . Subject willing able attend study visits/telephone contact adhere study assessments/procedures . 4 . Subject willing able provide write informed consent . 1 . Subject current evidence recent history clinically significant unstable disease ( COPD ) abnormality opinion Investigator would put subject risk would compromise quality study data ; include limit cardiovascular disease , myocardial infarction , cardiac failure , uncontrolled hypertension , life threaten arrhythmia , uncontrolled diabetes , neurologic neuromuscular disease , liver disease , gastrointestinal disease electrolyte abnormality . 2 . Subject primary diagnosis asthma . 3 . Subject history tuberculosis , bronchiectasis nonspecific pulmonary disease . 4 . Subject history urinary retention bladder neck obstruction type symptom . 5 . Subject history narrow angle glaucoma . 6 . Subject recent history ( previous 12 month ) excessive use abuse alcohol narcotic/illegal drug , assess Investigator . 7 . Subject history hypersensitivity intolerance aerosol medication , beta2 agonist , anticholinergic . 8 . Subject participate another investigational drug study drug receive within 30 day prior Screening , current participation another investigational drug trial . 9 . Subject staff member clinical site relative clinical site staff member .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic bronchitis</keyword>
</DOC>